Previously undetected Chlamydia trachomatis infection, immunity to heat shock proteins and tubal occlusion in women undergoing in-vitro fertilization.
The relationship between a previously undetected Chlamydia trachomatis infection, tubal infertility, immunity to heat shock proteins and subsequent in-vitro fertilization (IVF) outcome was evaluated. Women with tubal occlusion, with or without hydrosalpinges, and no history of C. trachomatis infection were tested for circulating antibodies to the human 60-kDa heat shock protein (Hhsp60), the C. trachomatis 10-kDa heat shock protein (Chsp10) and C. trachomatis surface antigens prior to their initial IVF cycle. Sera were obtained from 50 women whose male partners were infertile, 58 women with tubal occlusion but no hydrosalpinx and 39 women with tubal occlusions plus hydrosalpinx. Clinical pregnancies were documented in 68% of the women with male factor infertility. This was higher than the 43.1% rate in women with tubal occlusions (P = 0.04) and the 41% rate in women with hydrosalpinx (P = 0.02). C. trachomatis antibodies were present in one (2%) women with male factor infertility as opposed to 15 (25.9%) women with tubal occlusion (P = 0.003) and 13 (33%) with hydrosalpinx (P < 0.0001). Antibodies to Chsp10 were more prevalent in women with hydrosalpinx (46.8%) than in women with male factor infertility (P < 0.0001, 6%) or tubal occlusion (P = 0.0009, 15.5%). Hhsp60 antibodies were equally more prevalent in women with tubal occlusion plus (46.8%) or minus hydrosalpinx (41.4%) than in women with male factor infertility (P < 0.0002). Hhsp60 was more prevalent in those women positive for Chsp10 (P = 0.02) or C. trachomatis (P = 0.04) antibodies than in women lacking these antibodies. There was no relationship between any of the antibodies measured in sera and IVF outcome.
Spandorfer
S D
SD
Department of Obstetrics and Gynecology, Cornell University Medical College, New York, NY 10021, USA.
Neuer
A
A
LaVerda
D
D
Byrne
G
G
Liu
H C
HC
Rosenwaks
Z
Z
Witkin
S S
SS
D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D018835:Chaperonin 10 / Q000276:immunology; D018834:Chaperonin 60 / Q000276:immunology; D002690:Chlamydia Infections / Q000150:complications* / Q000276:immunology*; D002692:Chlamydia trachomatis / Q000378:metabolism; D003251:Constriction, Pathologic; D005184:Fallopian Tube Diseases / Q000276:immunology / Q000382:microbiology*; D005260:Female; D005307:Fertilization in Vitro; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007109:Immunity / Q000502:physiology*; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D007248:Infertility, Male; D008297:Male; D011247:Pregnancy; D011256:Pregnancy Outcome; D016896:Treatment Outcome
D000907:Antibodies, Bacterial; D018835:Chaperonin 10; D018834:Chaperonin 60; D006360:Heat-Shock Proteins